Nanotherapeutics for Treating Neurodegenerative Disorders

Dr. Manish K. Chourasia, is currently working as a Senior Principal Scientist in the Division of Pharmaceutics and Pharmacokinetics at CSIR-Central Drug Research Institute (CDRI), Lucknow, a premium drug research institute in India. He received his PhD in Pharmaceutical Sciences from Dr. Harisingh Gour University, Madhya Pradesh, India and carried out his post-doctoral studies at Department of Pharmacy, National University of Singapore, Singapore. Having acquired valuable experience in both industry and academia, he subsequently joined the role of a scientist at CSIR-CDRI almost two decades ago. He has played a significant role in advancing the field of nanoparticle-based drug delivery for breast cancer, aiming to enhance the therapeutic outcome. He has published 80+ scientific papers including high-impact journal reviews. He has supervised more than 50 MS students and PhD students.Prof. Shubhini A. Saraf is working as Director of the National Institute of Pharmaceutical Education and Research (NIPER), Raebareli (U.P.). Before joining NIPER, Raebareli, she worked as a Professor in the Department of Pharmaceutical Sciences and Director (R&D) at Babasaheb Bhimrao Ambedkar University (A Central University), Lucknow. She also served in various administrative positions at BBA University Lucknow and B.B.D.N.I.T.M. Lucknow including Head-Pharmaceutical Sciences, Dean- School of Biomedical and Pharmaceutical Sciences, Dean- School of Biosciences & Biotechnology, member of the Board of Management, Director, E.M.M.R.C. at BBAU, Lucknow and Director B.B.D.N.I.T.M. Lucknow. Prof. Shubhini is an alumnus of the Department of Pharmaceutical Sciences, Dr Harisingh Gour University, Sagar where she pursued her B. Pharm, M. Pharm, and Ph.D. in Pharmacy. She has more than 28 years of teaching and research experience. Her research interests include Nanotechnology & Drug Targeting as well as Technology Policy Interventions for Health Care. She has 167 papers, and 21 book chapters to her credit and is an active pharmacy professional.Yashwant Pathak is a Professor and Associate Dean for faculty affairs at the Taneja College of Pharmacy at the University of South Florida, Tampa, USA. Prof. Pathak is also an Adjunct Professor at the Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia. His area of research is in health care education, nanotechnology, drug delivery systems, and nutraceuticals. Dr. Mohini Chaurasia stands as a distinguished figure in the field of pharmaceutical education, currently holding the positions of Professor and Principal at Era College of Pharmacy, Era University, Lucknow, India. With a career spanning various academic institutions, including Amity University and Integral University, Dr. Chaurasia has garnered extensive experience, contributing significantly to the field. Her academic journey boasts a culmination in her current role, driving both research and institutional leadership. Dr. Chaurasia's expertise extends beyond teaching to innovative research, evident in her publications and patents. In the field of drug delivery, she has edited books like "Novel Carriers for Drug Delivery" and "Oral Modified Release Drug Delivery Systems," showcasing her depth of knowledge. Moreover, her research contributions include impactful chapters on drug delivery systems and nanotechnology applications in drug development. Beyond her scholarly pursuits, Dr. Chaurasia actively engages in various academic and administrative responsibilities, serving on boards, committees, and taking up leadership roles.

• 1. Concepts, types, and treatment strategies for neurodegenerative disorders2. Transport mechanisms of the Blood-Brain Barrier3. Need of nanotherapeutics against neurodegenerative disorders4. Nanotechnology mediated drug delivery for addressing protein aggregation5. Nanocarriers focusing on synuclein misfolding as a therapeutic target6. Therapeutic potential of stem cells derived nanocarriers in neurological disorders7. Emphasizing mitochondrial dysfunction and autophagy in the treatment of neurological disorders8. Nanocarriers assisted delivery of genetic material for the treatment of neurodegenerative disorders9. Nanotherapeutics targeting neuroinflammation10. Nanocarriers mediated DNA repair mechanism against neurological disorders11. Nanotherapy for targeted inhibition of PERK: Unravelling stress-induced endoplasmic reticulum kinase12. Targeting microglial inhibition via nanotechnology: A strategy to halt protein degradation13. Nanocarriers unveiling ferroptosis as a potential therapeutic target14. Proteostasis maintenance through nanocarriers: Mitigating protein misfolding, mitochondrial impairment, and oxidative stress15. Modulation of Hippo signaling pathway dysregulation through nanotechnology for neurodegenerative disorders16. Nanocarriers modulating fibrinolytic pathways for the treatment of various neurological disorders17. Targeting glial cells through nanotherapeutic strategies in neurological disorders18. Oligodendrocytes as an emerging therapeutic target in neurological disorders